<DOC>
	<DOC>NCT01808248</DOC>
	<brief_summary>This study is to evaluate the safety, tolerability, and antiviral efficacy of sofosbuvir (SOF) in combination with peginterferon alfa 2a (PEG) and ribavirin (RBV) administered for 12 weeks in participants with chronic genotype 2 or 3 hepatitis C virus (HCV) infection who have previously failed prior treatment with an interferon-based regimen.</brief_summary>
	<brief_title>Sofosbuvir (GS-7977) in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<mesh_term>Molecular Mechanisms of Pharmacological Action</mesh_term>
	<criteria>Infection with genotype 2 or 3 HCV infection Cirrhosis determination Individual is treatmentexperienced Screening laboratory values within defined thresholds Individual has not been treated with any investigational drug or device within 30 days of the Screening visit Use of highly effective contraception methods if female of childbearing potential or sexually active male Prior exposure to a directacting antiviral drug targeting the HCV NS5B polymerase Pregnant or nursing female or male with pregnant female partner Current or prior history of clinical hepatic decompensation History of clinicallysignificant illness or any other major medical disorder that may interfere with treatment, assessment, or compliance with the study protocol Excessive alcohol ingestion or significant drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>HCV genotype 2 (GT-2)</keyword>
	<keyword>HCV genotype 3 (GT-3)</keyword>
	<keyword>HCV</keyword>
	<keyword>Sustained Virologic Response</keyword>
	<keyword>Direct Acting Antiviral</keyword>
	<keyword>Combination Therapy</keyword>
	<keyword>Treatment-Na√Øve</keyword>
	<keyword>GS-7977</keyword>
	<keyword>Ribavirin</keyword>
	<keyword>RBV</keyword>
	<keyword>Peginterferon Alfa 2a</keyword>
	<keyword>PEG</keyword>
	<keyword>Additional relevant MeSH terms:</keyword>
	<keyword>Hepatitis</keyword>
	<keyword>Hepatitis A</keyword>
	<keyword>Hepatitis, Chronic</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Hepatitis C, Chronic</keyword>
	<keyword>Liver Diseases</keyword>
	<keyword>Digestive System Diseases</keyword>
	<keyword>Hepatitis, Viral, Human</keyword>
	<keyword>Virus Diseases</keyword>
	<keyword>Enterovirus Infections</keyword>
	<keyword>Picornaviridae Infections</keyword>
	<keyword>RNA Virus Infections</keyword>
	<keyword>Flaviviridae Infections</keyword>
	<keyword>Peginterferon alfa-2a</keyword>
	<keyword>Interferon-alpha</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Anti-Infective Agents</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Antimetabolites</keyword>
	<keyword>Molecular Mechanisms of Pharmacological Action</keyword>
	<keyword>Immunologic Factors</keyword>
	<keyword>Physiological Effects of Drugs</keyword>
</DOC>